Does the media favor SYRE or AGIO?

In the previous week, Agios Pharmaceuticals had 14 more articles in the media than Spyre Therapeutics. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 3 mentions for Spyre Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Spyre Therapeutics' score of 0.05 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMVT or AGIO?

In the previous week, Agios Pharmaceuticals had 6 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 11 mentions for Immunovant. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Immunovant's score of 0.01 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALKS or AGIO?

In the previous week, Alkermes had 9 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 26 mentions for Alkermes and 17 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Alkermes' score of 0.67 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 9 Very Positive mention(s) 6 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AGIO or RYTM?

In the previous week, Agios Pharmaceuticals had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 11 mentions for Rhythm Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Rhythm Pharmaceuticals' score of 0.44 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SRRK or AGIO?

In the previous week, Agios Pharmaceuticals had 9 more articles in the media than Scholar Rock. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 8 mentions for Scholar Rock. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Scholar Rock's score of 0.76 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Agios Pharmaceuticals (AGIO) Competitors

$34.19 -0.78 (-2.23%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$34.35 +0.16 (+0.46%)

As of 08:09 AM Eastern

Compare

AGIO vs. SYRE, IMVT, ALKS, RYTM, and SRRK

Should you buy Agios Pharmaceuticals stock or one of its competitors? Agios Pharmaceuticals's main competitors and comparable companies include Spyre Therapeutics (SYRE), Immunovant (IMVT), Alkermes (ALKS), Rhythm Pharmaceuticals (RYTM), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Spyre Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Spyre Therapeutics' return on equity of -30.74% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Spyre Therapeutics has a beta of 2.99, indicating that its share price is 199% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Agios Pharmaceuticals had 14 more articles in the media than Spyre Therapeutics. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 3 mentions for Spyre Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Spyre Therapeutics' score of 0.05 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A
Agios Pharmaceuticals	$54.03M	37.78	-$412.78M	-$7.01	N/A

Spyre Therapeutics presently has a consensus price target of $109.69, indicating a potential upside of 24.41%. Agios Pharmaceuticals has a consensus price target of $41.75, indicating a potential upside of 22.11%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Spyre Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Summary

Spyre Therapeutics beats Agios Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Immunovant currently has a consensus target price of $44.00, suggesting a potential upside of 27.39%. Agios Pharmaceuticals has a consensus target price of $41.75, suggesting a potential upside of 22.11%. Given Immunovant's stronger consensus rating and higher possible upside, research analysts clearly believe Immunovant is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Immunovant has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Immunovant has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Agios Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Agios Pharmaceuticals	$54.03M	37.78	-$412.78M	-$7.01	N/A

In the previous week, Agios Pharmaceuticals had 6 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 11 mentions for Immunovant. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Immunovant's score of 0.01 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are owned by institutional investors. 1.9% of Immunovant shares are owned by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Agios Pharmaceuticals beats Immunovant on 9 of the 16 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Alkermes has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.79	$241.66M	$0.38	110.87
Agios Pharmaceuticals	$54.03M	37.78	-$412.78M	-$7.01	N/A

Alkermes has a net margin of 3.96% compared to Agios Pharmaceuticals' net margin of -418.24%. Alkermes' return on equity of 4.15% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

In the previous week, Alkermes had 9 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 26 mentions for Alkermes and 17 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Alkermes' score of 0.67 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	9 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes currently has a consensus price target of $54.47, suggesting a potential upside of 29.29%. Agios Pharmaceuticals has a consensus price target of $41.75, suggesting a potential upside of 22.11%. Given Alkermes' stronger consensus rating and higher possible upside, equities analysts clearly believe Alkermes is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Alkermes has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

95.2% of Alkermes shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Alkermes beats Agios Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

In the previous week, Agios Pharmaceuticals had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 11 mentions for Rhythm Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Rhythm Pharmaceuticals' score of 0.44 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Rhythm Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	37.78	-$412.78M	-$7.01	N/A
Rhythm Pharmaceuticals	$189.76M	35.48	-$196.54M	-$3.11	N/A

Agios Pharmaceuticals presently has a consensus price target of $41.75, indicating a potential upside of 22.11%. Rhythm Pharmaceuticals has a consensus price target of $140.67, indicating a potential upside of 43.19%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

Agios Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market.

Summary

Rhythm Pharmaceuticals beats Agios Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scholar Rock has higher earnings, but lower revenue than Agios Pharmaceuticals. Scholar Rock is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Agios Pharmaceuticals	$54.03M	37.78	-$412.78M	-$7.01	N/A

In the previous week, Agios Pharmaceuticals had 9 more articles in the media than Scholar Rock. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 8 mentions for Scholar Rock. Agios Pharmaceuticals' average media sentiment score of 0.83 beat Scholar Rock's score of 0.76 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Scholar Rock presently has a consensus target price of $66.69, indicating a potential upside of 33.78%. Agios Pharmaceuticals has a consensus target price of $41.75, indicating a potential upside of 22.11%. Given Scholar Rock's stronger consensus rating and higher possible upside, equities analysts clearly believe Scholar Rock is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Scholar Rock has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Summary

Scholar Rock beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGIO vs. The Competition

Export

Metric	Agios Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.09B	$3.98B	$7.31B	$13.28B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-4.88	13.88	274.10	25.70
Price / Sales	37.78	1,437.48	672.61	90.85
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.67	15.45	10.48	6.32
Net Income	-$412.78M	-$22.82M	$3.49B	$359.73M
7 Day Performance	1.73%	-1.68%	-0.68%	0.17%
1 Month Performance	4.75%	-6.15%	-3.18%	-3.27%
1 Year Performance	-8.39%	30.67%	15.13%	5.58%

Agios Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGIO Agios Pharmaceuticals	3.33 of 5 stars	$34.19 -2.2%	$41.75 +22.1%	-9.7%	$2.09B	$54.03M	N/A	540	Positive News Analyst Forecast Analyst Revision
SYRE Spyre Therapeutics	2.432 of 5 stars	$90.80 +0.2%	$109.69 +20.8%	+450.4%	$7.97B	N/A	N/A	112
IMVT Immunovant	2.8163 of 5 stars	$37.66 +0.8%	$44.00 +16.8%	+131.8%	$7.72B	N/A	N/A	315	Trending News Analyst Forecast Gap Down
ALKS Alkermes	3.525 of 5 stars	$45.83 -0.3%	$54.56 +19.1%	+51.8%	$7.71B	$1.48B	120.61	2,050	Trending News Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.8168 of 5 stars	$102.44 -2.2%	$140.67 +37.3%	-0.5%	$7.18B	$189.76M	N/A	414

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGIO) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. SYRE, IMVT, ALKS, RYTM, and SRRK

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Immunovant?

Summary

How does Agios Pharmaceuticals compare to Alkermes?

Summary

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Agios Pharmaceuticals compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. SYRE, IMVT, ALKS, RYTM, and SRRK

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Is SYRE or AGIO more profitable?

Which has more risk & volatility, SYRE or AGIO?

Do insiders & institutionals hold more shares of SYRE or AGIO?

Does the media favor SYRE or AGIO?

Which has better valuation and earnings, SYRE or AGIO?

Do analysts recommend SYRE or AGIO?

Summary

How does Agios Pharmaceuticals compare to Immunovant?

Do analysts recommend IMVT or AGIO?

Which has more risk & volatility, IMVT or AGIO?

Is IMVT or AGIO more profitable?

Which has better valuation and earnings, IMVT or AGIO?

Does the media refer more to IMVT or AGIO?

Do insiders & institutionals hold more shares of IMVT or AGIO?

Summary

How does Agios Pharmaceuticals compare to Alkermes?

Which has better valuation and earnings, ALKS or AGIO?

Is ALKS or AGIO more profitable?

Does the media prefer ALKS or AGIO?

Do analysts prefer ALKS or AGIO?

Which has more risk and volatility, ALKS or AGIO?

Do institutionals & insiders hold more shares of ALKS or AGIO?

Summary

How does Agios Pharmaceuticals compare to Rhythm Pharmaceuticals?

Does the media prefer AGIO or RYTM?

Is AGIO or RYTM more profitable?

Which has higher earnings and valuation, AGIO or RYTM?

Do analysts recommend AGIO or RYTM?

Which has more volatility and risk, AGIO or RYTM?

Summary

How does Agios Pharmaceuticals compare to Scholar Rock?

Do institutionals and insiders believe in SRRK or AGIO?

Which has better earnings and valuation, SRRK or AGIO?

Does the media favor SRRK or AGIO?

Which has more risk and volatility, SRRK or AGIO?

Do analysts rate SRRK or AGIO?

Is SRRK or AGIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools